Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis
Public ClinicalTrials.gov record NCT03058744. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Open Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis
Study identification
- NCT ID
- NCT03058744
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Enrollment
- 94 participants
Conditions and interventions
Conditions
Interventions
- IDP-118 Lotion Drug
- HP Monad Lotion Drug
- Ultravate Cream Drug
- Tazorac Cream Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2015
- Primary completion
- Nov 30, 2016
- Completion
- Dec 31, 2016
- Last update posted
- Jun 8, 2017
2015 – 2017
United States locations
- U.S. sites
- 12
- U.S. states
- 7
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Valeant Site 12 | Anaheim | California | 92801 | — |
| Valeant Site 05 | Encino | California | 91436 | — |
| Valeant Site 01 | San Diego | California | 92093 | — |
| Valeant Site 07 | Santa Rosa | California | 95401 | — |
| Valeant Site 10 | Orange Park | Florida | 32065 | — |
| Valeant Site 09 | Sanford | Florida | 32771 | — |
| Valeant Site 08 | Atlanta | Georgia | 30301 | — |
| Valeant Site 04 | Plainfield | Indiana | 46168 | — |
| Valeant Site 06 | New York | New York | 10001 | — |
| Valeant Site 11 | Philadelphia | Pennsylvania | 19019 | — |
| Valeant Site 03 | Austin | Texas | 73301 | — |
| Valeant Site 02 | Katy | Texas | 77449 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03058744, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 8, 2017 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03058744 live on ClinicalTrials.gov.